Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604397 | 0.85 | SMN1; SMN2 (0.68) | ALDH1A1PARP10MAPTRAB9AHPGD | |
| SCHEMBL3604393 | 0.85 | SMN1; SMN2 (0.68) | ALDH1A1PARP10MAPTRAB9AHPGD | |
| SCHEMBL1641119 | 0.85 | CES2 (0.61) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL12453 | 0.85 | CES2 (0.61) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL5217024 | 0.85 | CES2 (0.61) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL21456599 | 0.84 | KDM4E (0.43) | CES2CES1ALDH1A1CA1CA2 | |
| SCHEMBL28513928 | 0.84 | CES2 (0.55) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL22548771 | 0.84 | PARP10 (0.61) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL9196872 | 0.83 | KDM4E (0.64) | ALDH1A1CYP1A2MAPTMEN1LMNA | |
| SCHEMBL9593388 | 0.83 | KDM4E (0.64) | ALDH1A1CYP1A2MAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | claimed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | claimed |
| CN-119263946-A | Preparation method of alpha-acyloxyketone compound | 华南师范大学 | 2025-01-07 | — | — | CN | disclosed |
| CN-117603436-A | Polymer, modified polyurethane elastomer and preparation method thereof | 北京大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-114790159-B | Diphenyl ketone selenoethyl compound and preparation method and application thereof | 合肥学院 | 2023-08-11 | — | — | CN | disclosed |
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | disclosed |
| CN-115040497-A | Application of paeonol derivative in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-09-13 | — | — | CN | disclosed |
| CN-114790159-A | Diphenyl ketone selenide compound and preparation method and application thereof | 合肥学院 | 2022-07-26 | — | — | CN | disclosed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | disclosed |
| CN-108083999-B | Green preparation method of alpha-hydroxyketone | 西北师范大学 | 2020-08-11 | — | — | CN | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2568953-A2 | TRIAZINES AS REACTION ACCELERATORS | Merck Patent GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| WO-2011141111-A2 | TRIAZINES AS REACTION ACCELERATORS | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | WO | disclosed |
| EP-1892573-B1 | Photopolymerizable composition comprising fine particles of organic pigment | FUJIFILM CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-5668614-A | Pixelized liquid crystal display materials including chiral material adopted to change its chirality upon photo-irradiation | KENT STATE UNIVERSITY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5409952-A | Anticancer agents | ADIR ET COMPAGNIE (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0454587-A1 | Heterocyclic derivatives: 2-styryl-4H-1-benzopyran-4-ons, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | CES2 49/4885CES1 64/4885ALDH1A1 699/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | CES2 49/4885CES1 64/4885ALDH1A1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.